Abstract
Introduction: Patients with familial hypercholesterolemia (FH) are at increased risk of premature atherosclerotic cardiovascular disease (ASCVD). Aim of study: To perform a retrospective analysis of data to assess the effects of individual lipoproteins and other risk factors (RFs) on the development of ASCVD and to compare these parameters in individuals with versus without ASCVD. Patients and methods: Our study group included a total of 1,236 patients with FH (395 men and 841 women with a mean age of 44.8 ± 16.7 years) attending a single lipid clinic. The diagnosis of FH was established using the Dutch Lipid Clinic Network score (DLCN). Among the 1236 FH patients, 1,008 of them [854 suspected with LDL receptor-mediated FH and 154 with familial defective apolipoprotein B-100 (FDB)] were genetically analysed. Their RFs were assessed based on the patients’ clinical characteristics. Results: While patients with ASCVD had higher baseline LDL-C, TC, TG and Lp(a) compared with patients without this diagnosis, this ratio was just the opposite by the follow-up. The highest statistically significant differences were seen in the baseline levels of Lp(a) and, quite surprisingly, TG. Except for Lp(a), the levels of all lipid parameters declined significantly over time. While the incidence of diabetes and arterial hypertension was not higher in our group compared with the general population, these patients were at a more significant risk of ASCVD. Conclusion: Familial hypercholesterolemia is a major RF for the development of ASCVD. While our analysis confirmed the important role of LDL-C, it also corroborated a strong correlation between ASCVD and other lipid parameters, and Lp(a) and TG in particular. Familial hypercholesterolemia is not the only RF and, to reduce cardiovascular risk of their patients, physicians have to search for other potential RFs. Patients diagnosed to have FH benefit from attending a specialized lipid clinic perse.
Highlights
Patients with familial hypercholesterolemia (FH) are at increased risk of premature atherosclerotic cardiovascular disease (ASCVD)
The typical FH patient is predestined to have high LDL cholesterol (LDL-C) levels since childhood considerably raising the risk of premature atherosclerotic cardiovascular disease (ASCVD) (The Lipid Research Clinic, 1984; Watts et al, 2016; Ference et al, 2017)
The Center was being attended by a large number of patients with familial hypercholesterolemia; the duration of their follow-up has varied substantially as, while some patients have been taken care of for decades, the follow-up period of other patients has not been longer than 2 years
Summary
Patients with familial hypercholesterolemia (FH) are at increased risk of premature atherosclerotic cardiovascular disease (ASCVD). The typical FH patient is predestined to have high LDL cholesterol (LDL-C) levels since childhood considerably raising the risk of premature atherosclerotic cardiovascular disease (ASCVD) (The Lipid Research Clinic, 1984; Watts et al, 2016; Ference et al, 2017). All patients diagnosed with FH are automatically at least at high risk of developing ASCVD (Visseren et al, 2021). All FH patients require, in particular, an early diagnosis and initiation of lipid-lowering therapy as soon as possible. To achieve the target levels of LDLC, combination lipid-lowering therapy is quite often necessary; most often a combination of a statin with ezetimibe or, alternatively, with a PCSK9 inhibitor, is used (Visseren et al, 2021)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
